Clinical Trial Details

Trial ID: L0246
Source ID: NCT02856555
Associated Drug: Firsocostat
Title: Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis
Acronym: --
Status: Completed
Study Results: Has Results
Results: https://ClinicalTrials.gov/show/NCT02856555/results
Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: Firsocostat|Drug: Placebo
Outcome Measures: Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Sponsor/Collaborators: Gilead Sciences
Gender: All
Age: 18 Years to 75 Years ?? (Adult, Older Adult)
Phases: Phase 2
Enrollment: 127
Study Type: Interventional
Study Designs: Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
Start Date: August 8, 2016
Completion Date: July 18, 2017
Results First Posted: July 24, 2020
Last Update Posted: July 24, 2020
Locations: Coronado, California, United States|Foster City, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Rialto, California, United States|San Diego, California, United States|San Diego, California, United States|San Francisco, California, United States|San Francisco, California, United States|Miami, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Kansas City, Missouri, United States|New York, New York, United States|Durham, North Carolina, United States|Statesville, North Carolina, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Germantown, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Live Oak, Texas, United States|San Antonio, Texas, United States|Murray, Utah, United States|Falls Church, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Richland, Washington, United States|Seattle, Washington, United States
URL: https://ClinicalTrials.gov/show/NCT02856555

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D136 Firsocostat Chemical drug DB16166 ACC inhibitor Enhance lipid metabolism Under clinical trials Details